Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Carcinoma, Ductal, Breast
Interventions: PROCEDURE: Biopsy before and after three weeks of study treatment|DRUG: paclitaxel|DRUG: lapatinib|DRUG: trastuzumab
Sponsor: West German Study Group
Collaborators: GlaxoSmithKline